MultiCell Technologies, Inc. - EX-99.1 - The MCIT Presentation by MultiCell Immunotherapeutics, Inc. was released on September 26, 2016. - September 26, 2016
ADCETRIS (brentuximab vedotin) plus chemotherapy is the first approved treatment in over 40 years for adults with newly diagnosed Stage 3 or 4 classical Hodgkin lymphoma, and was shown to be better than a traditional treatment in helping people reduce the chance of their cancer getting worse or needing more treatment.
Classical Hodgkin lymphoma, also called Hodgkin's lymphoma, is a cancer of the blood. It starts when lymphocytes, a type of white blood cell, grow out of control. Making treatment decisions for Stage 3 or 4 classical Hodgkin lymphoma Stage 3 or 4 classical Hodgkin lymphoma is cancer that has spread to lymph nodes or other organs throughout the body. By learning all you can about your stage of cancer and your treatment options, you and your doctor can work together to find a treatment that’s right for you.
When choosing treatment, you’ll want to understand
How well the treatment works to stop or slow the progression of the cancer The chance of needing additional chemotherapy or stem cell transplant The chance of the cancer coming back What side effects are possible
ADCETRIS® (brentuximab vedotin) for injection logo
CD30-directed treatment, focused on you
Classical Hodgkin Lymphoma
Certain T-cell Lymphomas
Genentech takes the health and safety of our patients, customers, employees, and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.
Seattle Genetics logo ADCETRIS and its logo, Seagen Secure and its logo, and Seagen and , are US registered trademarks of Seagen Inc.
Market Data 
Markets 
AI
